What Causes Hand Eczema in Women—and How to Treat It

Hand eczema in women is a common inflammatory skin condition characterized by redness, scaling, itching, and sometimes cracking or blistering of the skin on the hands. It is notably more prevalent among women than men—particularly those aged 20 to 50—and often reflects a complex interplay of intrinsic (endogenous) and extrinsic (exogenous) factors.

Key contributing causes include frequent exposure to irritants such as soaps, detergents, disinfectants, and cleaning agents—especially in occupational settings like healthcare, hairdressing, food service, and domestic work. Women are disproportionately affected due to both higher occupational exposure and greater frequency of household cleaning tasks. Allergic contact dermatitis—triggered by allergens like nickel, fragrances, preservatives (e.g., methylisothiazolinone), or rubber accelerators—also plays a significant role. Additionally, atopic predisposition (e.g., personal or family history of asthma, allergic rhinitis, or atopic dermatitis) increases susceptibility. Environmental factors such as cold, dry weather and repeated hand washing further compromise the skin barrier, facilitating inflammation and sensitization.

Treatment follows a tiered, individualized approach centered on avoidance, barrier protection, and anti-inflammatory therapy. First-line management involves strict irritant avoidance—using fragrance-free, pH-balanced cleansers; wearing protective gloves (cotton liners under vinyl or nitrile gloves for wet work); and applying emollients multiple times daily, especially after hand washing. Topical corticosteroids remain the cornerstone for active flares: mid- to high-potency formulations (e.g., betamethasone dipropionate 0.05%) are typically prescribed for short-term use (1–2 weeks), followed by tapering or switch to topical calcineurin inhibitors (e.g., tacrolimus 0.1%) for maintenance in sensitive areas or chronic cases. For severe, recalcitrant disease, systemic therapies—including oral corticosteroids (short course), alitretinoin (a pan-retinoid approved specifically for chronic hand eczema), or biologics such as dupilumab (under investigation in clinical trials)—may be considered under dermatologic supervision.

Long-term prognosis depends heavily on early intervention, consistent trigger identification (often aided by patch testing), and adherence to preventive strategies. Without proper management, chronic hand eczema can lead to lichenification, fissuring, secondary infection, and substantial impact on quality of life and occupational function.